Loading stock data…
Pharvaris N.V (PHVS)
$34.71+0.70 (+2.06%)
Market ClosedLast close Jun 29
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharvaris N.V. in the Healthcare sector is trading at $34.71 with a market capitalization of $2.2B. Wall Street consensus targets $46.23 (13 analysts), implying a +33.2% move over the next 12 months. The stock is currently near its 52-week high of $35.33, remaining 29.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.27M↑ | -$47.60M↓ | -$39.66M↑ | -$40.37M↑ | -$42.19M |
| Net Income | -$39.20M↑ | -$46.74M↓ | -$37.14M↑ | -$45.48M↑ | -$46.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.32%
Volume
Today's trading volume
723,208
Recent News
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
Pharvaris (NasdaqGS:PHVS) has completed a substantial equity offering to support late stage development of its lead treatment for hereditary angioedema. The company is preparing regulatory submissions, including a planned new drug application, and progressing Phase 3 trials for hereditary and acquired angioedema. This funding event comes as Pharvaris positions itself for potential commercialization of its lead product. Pharvaris enters this phase with its stock at $32.94 and a 3 year return...
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones.
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.